ONCY
NASDAQOncolytics Biotech Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$0.85-0.22 (-20.31%)
2026-03-042026-06-05
News · 26 weeks153+283%
2025-12-142026-06-07
Mix8990d
- Other49(55%)
- SEC Filings19(21%)
- Insider18(20%)
- M&A1(1%)
- Market1(1%)
- Leadership1(1%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Mcadory John Bearden3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Pisano Wayne4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Rigby Jonathan4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Holtham Angela4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Parsons James T.4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business Officer Aromando Andrew4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Look Kirk4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Kelly Jared4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 3 filed by new insider Glover Stephen C.3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Andrews Patricia S4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Seizinger Bernd R.4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Chief Technology Officer Hagerman Allison4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Glover Stephen C.4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Director Brown Deborah Margaret4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Heineman Thomas Charles4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Mcadory John Bearden4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating OfficerSAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer ("COO"). Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including se
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted ApproachesSAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, today announced initial data from a preclinical study evaluating pelareorep in combination with RAS inhibitor modalities in a solid tumor model, which demonstrate evidence of greater anti-tumor activity in combination than with the individual approaches alone. Pelareorep is an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infilt
- NEWSFrom Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology StorySAN DIEGO, CA / ACCESS Newswire / May 26, 2026 / Biotech investors spend enormous amounts of time searching for "the next big thing." Most never stop to ask a more important question:What does sophisticated pharmaceutical money actually look for before billions of dollars start moving?That distinction matters.Because the biotechnology graveyard is filled with companies that had interesting science but never figured out how to position themselves strategically inside the larger oncology ecosystem. Great science alone is not always enough. The companies that ultimately command attention tend to develop something bigger: platform utility, combination relevance, strategic flexibility, and data c
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal TumorsSAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, today announced translational data from the GOBLET and AWARE-1 trials will be presented at the 2026 American Society of Clinical Oncology ("ASCO") Annual Meeting at McCormick Place, Chicago, Illinois, from May 29-June 2, 2026. Pelareorep is an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. "These finding
- SECSEC Form 10-Q filed by Oncolytics Biotech Inc.10-Q - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PR"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesIssued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m
ONCY FAQ
6 questionsWhat does Oncolytics Biotech Inc. do?
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC...Where does ONCY stock trade?
Oncolytics Biotech Inc. (ONCY) is listed on NASDAQ.What sector and industry is ONCY in?
Oncolytics Biotech Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ONCY?
Oncolytics Biotech Inc. has had 2 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $700.00 price target on 2025-08-13. Recent price targets range from $300.00 to $700.00.What companies are similar to ONCY?
Notable peers in the same industry include LEGN (Legend Biotech Corporation), PBYI (Puma Biotechnology Inc), FBIO (Fortress Biotech Inc.), MBRX (Moleculin Biotech Inc.). Compare ONCY side-by-side with any of them on Quantisnow.How can I track ONCY on Quantisnow?
Quantisnow aggregates Oncolytics Biotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ONCY to receive live email and push alerts on every new disclosure.